Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting

ByConnor Hodde

This study was an evaluation, at 12 months follow-up, of anti VEGF treatment for diabetic macular edema conducted in a real world setting.  To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated…

Macular Degeneration Association Issues Urgent Supplement Warning for Patients

ByConnor Hodde

The Macular Degeneration Association, a nonprofit dedicated to preventing blindness, today issued an urgent warning to patients suffering from a form of the disease known as “intermediate dry age-related macular degeneration.”  MDA leaders and ophthalmologists are advising patients to talk with their doctors about a proven and commonly prescribed vitamin supplement containing zinc, an ingredient…

Pharma News: Bayer, Johns Hopkins partner to develop new ophthalmic therapies

ByConnor Hodde

Bayer HealthCare has entered into a five-year collaboration agreement with The Johns Hopkins University in Baltimore, US, for the discovery and development of new therapies in ophthalmology targeting retinal diseases.  Both the parties will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with high unmet…

New Trial Shows Drugs are Effective for Diabetic Macular Edema

ByConnor Hodde

 Diabetes is a significant risk factor for developing eye diseases. The most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy.  Americans with diabetic retinopathy have diabetic macular edema (DME) in which fluid leaks into the macula, the area of the retina used when looking straight ahead.  Over the past few…